GPR84 antagonist 9
GPR84 antagonist 9 is an orally active GPR84 antagonist with an IC50 value of 12 nM. By antagonizing the GPR84 receptor, GPR84 antagonist 9 blocks immune cell migration, M1 polarization, and the release of inflammatory factors (IL1β/TNFα) induced by medium-chain free fatty acids (MCFFAs) and other substances, thereby comprehensively inhibiting inflammatory and fibrotic responses. GPR84 antagonist 9 can be used in the research of inflammation-driven pain disorders, including neuropathic pain disorders, Fabry disease, gout, and bladder pain syndrome.
For research use only. We do not sell to patients.
- CAS No.: 2654791-96-3
- Formula: C25H26F3N5O4
- Molecular Weight:517.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
IL-1β |
TNF-α |
In Vitro
GPR84 antagonist 9 (Compound 320) (0.07 nM-20 μM; 30 min incubation, followed by 30 min agonist stimulation) inhibits Gi-coupled GPR84 receptor activation and restores intracellular cAMP levels in CHO-K1 cells stably expressing the GPR84 receptor[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
GPR84 antagonist 9 (10 mg/kg-250 mg/kg; p.o.; once daily; administered from day 10 to day 28) significantly enhances the analgesic effect of increasing mechanical pain threshold in a Streptozotocin (HY-13753)-induced rat model of diabetic neuropathic pain[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley male rats (~9 weeks old) were injected with 2 mg/kg oxaliplatin once daily for 5 days[1]
-
Dosage:10 mg/kg, 30 mg/kg, 90 mg/kg
-
Administration:p.o.; once daily; starting from day 1 and evaluated up to day 28
-
Result:Significantly increased the mechanical paw withdrawal threshold to von Frey filament stimulation, demonstrating analgesic efficacy at doses of 30 mg/kg and 90 mg/kg.
-
Animal Model:Sprague Dawley male rats were given 60 mg/kg Streptozotocin (STZ) on day 0[1]
-
Dosage:10 mg/kg, 90 mg/kg, 150 mg/kg, 250 mg/kg
-
Administration:p.o.; once daily; treated from day 10 up to day 28 post modeling.
Results -
Result:Significantly increased the pain withdrawal threshold to mechanical stimulation in diabetic rats at doses of 90, 150, and 250 mg/kg.
Chemical Information
-
CAS No. 2654791-96-3
-
Molecular Weight 517.50
-
Formula C25H26F3N5O4
-
SMILES
FC(F)(F)C1=C(C(NCC2=NC=C(C3CC3)N=C2)=O)OC4=C1C5=NN(C[C@@H]6OCCOC6)C=C5[C@H](C)C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GPR84 antagonist 9 Related Classifications
HY-161682 Related Classifications
Powered by Bioz